Compare ClearPoint Neuro Inc (CLPT) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs J M Smucker Co — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while J M Smucker Co trades at $108.33 (market cap $11.63B). The key difference: J M Smucker Co is far larger — about 24.3× ClearPoint Neuro Inc's market cap, and J M Smucker Co pays a 4.04% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | SJM | |
|---|---|---|
Market Cap | $478.63M | $11.63B |
Sector | Health | Consumer Staples |
52-Week High | $29.60 | $117.05 |
52-Week Low | $8.66 | $89.53 |
Enterprise Value | $506.63M | $18.66B |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
SJM trades at $110.53, down 0.96% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed earnings with Q4 2026 beating estimates but Q3 2025 missing, alongside a net loss of $1.23 billion in 2025. Recent news highlights Uncrustables as a growth driver, while the Twinkie acquisition faces challenges. Cash flow improved to a net positive $7.90 million in 2025, though debt-to-asset ratio rose to 43.71%.
Outlook is cautious with analyst consensus at Buy (51.61%) and a $123.18 price target, but risks include high debt, margin pressure, and FY2027 sales guidance down 3-4%. The dividend yield of about 1% offers income, but growth depends on coffee margin recovery and Uncrustables expansion amid competitive headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
